Wire · opportunities
WCLC 2026 Opens in Seoul: Targeted Therapy Moves Earlier as SCLC Enters a New ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 September 2026 · Fusion42 review
WCLC 2026 in Seoul highlights a new therapeutic era for small cell lung cancer with DLL3-directed T-cell engagers and B7-H3-directed antibody-drug conjugates moving earlier into treatment lines, challenging existing chemotherapy standards. Phase III trials show these targeted therapies improve survival and may reshape treatment protocols by integrating molecular targeting before disease progression.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.
◆ ◆ The Wire takeaway
Your lung cancer biotech now faces a market where targeted DLL3 and B7-H3 therapies are displacing old chemo options. Start mapping patient pathways to align molecular targeting earlier in treatment to lead the package.
◆ Coverage
1 source · 13 Sep 2026
◆ Related on Wire
◆ Topics